Clinical trial of 5% imiquimod cream for eleven cases of infantile hemangioma

Hyo Hyun Ahn, Yong Joo Kim, Eul Sang Hwang, Il-Hwan Kim

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Infantile hemangioma is a common benign tumor with preponderance in females. Even though most of them have self-limiting course after growing phase, many parents seek more effective and less aggressive therapy. Motivated by a report on the experience of successful treatment with imiquimod, we planned to confirm the beneficial effect of imiquimod on the regression of infantile hemangioma. Objective: To enhance the noninvasive treatment modality of infantile hemangioma. Methods: Eleven patients with various ages were enrolled in this study. Eight female and three male patients applied 5% imiquimod cream every other day or daily. Results: There was no statistically significant difference of treatment results between both sexes. The number of lesions and locations didn't alter the outcome. But, the growing phase versus regression phase affected the response to treatment significantly after two months of application. As a whole, most of the patients tolerated the imiquimod well. Three of them experienced mild scales and erosions. One showed shallow ulcers and crusts that needed medical treatments. But, by reducing the frequency of application and some dressings, all the complications were managed well and didn't hinder the therapy. There were no significant systemic adverse effects. Conclusion: Imiquimod is effective for infantile hemangioma regardless of site of occurrence, especially when used early in growing phase. It is noninvasive and relatively safe method. For a beneficial effect, the therapy must be continued for at least two months.

Original languageEnglish
Pages (from-to)718-723
Number of pages6
JournalKorean Journal of Dermatology
Volume42
Issue number6
Publication statusPublished - 2004 Jun 1

Fingerprint

imiquimod
Hemangioma
Clinical Trials
Therapeutics
Bandages
Ulcer
Parents

Keywords

  • Hemangioma of infancy
  • Therapy

ASJC Scopus subject areas

  • Dermatology

Cite this

Clinical trial of 5% imiquimod cream for eleven cases of infantile hemangioma. / Ahn, Hyo Hyun; Kim, Yong Joo; Hwang, Eul Sang; Kim, Il-Hwan.

In: Korean Journal of Dermatology, Vol. 42, No. 6, 01.06.2004, p. 718-723.

Research output: Contribution to journalArticle

@article{6df77a5f2cd249ccb2942066572a61db,
title = "Clinical trial of 5{\%} imiquimod cream for eleven cases of infantile hemangioma",
abstract = "Background: Infantile hemangioma is a common benign tumor with preponderance in females. Even though most of them have self-limiting course after growing phase, many parents seek more effective and less aggressive therapy. Motivated by a report on the experience of successful treatment with imiquimod, we planned to confirm the beneficial effect of imiquimod on the regression of infantile hemangioma. Objective: To enhance the noninvasive treatment modality of infantile hemangioma. Methods: Eleven patients with various ages were enrolled in this study. Eight female and three male patients applied 5{\%} imiquimod cream every other day or daily. Results: There was no statistically significant difference of treatment results between both sexes. The number of lesions and locations didn't alter the outcome. But, the growing phase versus regression phase affected the response to treatment significantly after two months of application. As a whole, most of the patients tolerated the imiquimod well. Three of them experienced mild scales and erosions. One showed shallow ulcers and crusts that needed medical treatments. But, by reducing the frequency of application and some dressings, all the complications were managed well and didn't hinder the therapy. There were no significant systemic adverse effects. Conclusion: Imiquimod is effective for infantile hemangioma regardless of site of occurrence, especially when used early in growing phase. It is noninvasive and relatively safe method. For a beneficial effect, the therapy must be continued for at least two months.",
keywords = "Hemangioma of infancy, Therapy",
author = "Ahn, {Hyo Hyun} and Kim, {Yong Joo} and Hwang, {Eul Sang} and Il-Hwan Kim",
year = "2004",
month = "6",
day = "1",
language = "English",
volume = "42",
pages = "718--723",
journal = "Korean Journal of Dermatology",
issn = "0494-4739",
publisher = "Korean Dermatological Association",
number = "6",

}

TY - JOUR

T1 - Clinical trial of 5% imiquimod cream for eleven cases of infantile hemangioma

AU - Ahn, Hyo Hyun

AU - Kim, Yong Joo

AU - Hwang, Eul Sang

AU - Kim, Il-Hwan

PY - 2004/6/1

Y1 - 2004/6/1

N2 - Background: Infantile hemangioma is a common benign tumor with preponderance in females. Even though most of them have self-limiting course after growing phase, many parents seek more effective and less aggressive therapy. Motivated by a report on the experience of successful treatment with imiquimod, we planned to confirm the beneficial effect of imiquimod on the regression of infantile hemangioma. Objective: To enhance the noninvasive treatment modality of infantile hemangioma. Methods: Eleven patients with various ages were enrolled in this study. Eight female and three male patients applied 5% imiquimod cream every other day or daily. Results: There was no statistically significant difference of treatment results between both sexes. The number of lesions and locations didn't alter the outcome. But, the growing phase versus regression phase affected the response to treatment significantly after two months of application. As a whole, most of the patients tolerated the imiquimod well. Three of them experienced mild scales and erosions. One showed shallow ulcers and crusts that needed medical treatments. But, by reducing the frequency of application and some dressings, all the complications were managed well and didn't hinder the therapy. There were no significant systemic adverse effects. Conclusion: Imiquimod is effective for infantile hemangioma regardless of site of occurrence, especially when used early in growing phase. It is noninvasive and relatively safe method. For a beneficial effect, the therapy must be continued for at least two months.

AB - Background: Infantile hemangioma is a common benign tumor with preponderance in females. Even though most of them have self-limiting course after growing phase, many parents seek more effective and less aggressive therapy. Motivated by a report on the experience of successful treatment with imiquimod, we planned to confirm the beneficial effect of imiquimod on the regression of infantile hemangioma. Objective: To enhance the noninvasive treatment modality of infantile hemangioma. Methods: Eleven patients with various ages were enrolled in this study. Eight female and three male patients applied 5% imiquimod cream every other day or daily. Results: There was no statistically significant difference of treatment results between both sexes. The number of lesions and locations didn't alter the outcome. But, the growing phase versus regression phase affected the response to treatment significantly after two months of application. As a whole, most of the patients tolerated the imiquimod well. Three of them experienced mild scales and erosions. One showed shallow ulcers and crusts that needed medical treatments. But, by reducing the frequency of application and some dressings, all the complications were managed well and didn't hinder the therapy. There were no significant systemic adverse effects. Conclusion: Imiquimod is effective for infantile hemangioma regardless of site of occurrence, especially when used early in growing phase. It is noninvasive and relatively safe method. For a beneficial effect, the therapy must be continued for at least two months.

KW - Hemangioma of infancy

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=4143098050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4143098050&partnerID=8YFLogxK

M3 - Article

VL - 42

SP - 718

EP - 723

JO - Korean Journal of Dermatology

JF - Korean Journal of Dermatology

SN - 0494-4739

IS - 6

ER -